Subanesthetic ketamine does not affect 11C-flumazenil binding in humans

Anesth Analg. 2005 Sep;101(3):722-725. doi: 10.1213/01.ANE.0000156951.83242.8D.

Abstract

Positron emission tomography (PET) studies suggest that propofol and inhaled anesthetics increase (11)C-flumazenil binding in the living human brain, thus supporting the involvement of gamma-aminobutyric acid type A (GABA(A)) receptors in the mechanism of action of these drugs. Ketamine produces its anesthetic effects primarily by N-methyl-d-aspartate receptor antagonism, but it may also have GABA(A) receptor agonistic properties. By using PET, we studied the cerebral (11)C-flumazenil binding in 10 healthy subjects before and during a subanesthetic racemic ketamine infusion reaching a serum concentration of 350 +/- 42 ng/mL. Ketamine did not affect (11)C-flumazenil binding to GABA(A) receptor in the brain, indicating that this mechanism is of minor importance in the actions of subanesthetic ketamine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Brain / drug effects
  • Brain / metabolism*
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / pharmacology*
  • Flumazenil / pharmacokinetics*
  • GABA Modulators / pharmacokinetics*
  • Humans
  • Infusions, Intravenous
  • Ketamine / administration & dosage
  • Ketamine / pharmacology*
  • Male
  • Positron-Emission Tomography
  • Receptors, GABA-A / drug effects

Substances

  • Excitatory Amino Acid Antagonists
  • GABA Modulators
  • Receptors, GABA-A
  • Flumazenil
  • Ketamine